Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2017-06-28 Investor Presentation
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Pharmaxis Investor Presentation 23 pages 832.3KB
Investor Presentation Classification · 95% confidence The document is a detailed corporate presentation or report describing Pharmaxis' business overview, drug development pipeline, management team, partnerships, financial strength, and product portfolio. It includes extensive information on drug discovery strategy, clinical trial phases, collaborations, and market opportunities. The content is comprehensive and includes financial highlights and strategic business information, but it does not appear to be a formal regulatory filing like an Annual Report (10-K) or Interim Report (IR). It is not a transcript, audit report, or a simple announcement. The length (15,000 characters) and depth suggest it is a detailed Investor Presentation (IP) aimed at providing investors with a thorough understanding of the company's operations, strategy, and financial position. There is no indication that this is a report publication announcement or a certification document. Therefore, the best fit is Investor Presentation (IP).
2017-06-28 English
Pharmaxis Announces Results of Pivotal CF Clinical Trial 4 pages 142.7KB
Capital/Financing Update Classification · 85% confidence The document is a media release announcing the results of a pivotal Phase 3 clinical trial for Bronchitol, a pharmaceutical product by Pharmaxis. It details the trial design, primary and secondary endpoints, demographics, and safety profile. The document is not a full financial report, regulatory filing, or management discussion. It is a press release focused on clinical trial results and future regulatory submission plans. It does not contain financial statements or detailed financial analysis, nor is it an announcement of a shareholder meeting or voting results. The content aligns best with a Capital/Financing Update (CAP) as it relates to clinical trial results that impact the company's product pipeline and potential market approval, which are material to investors and financing considerations. The document length and detail exceed a brief announcement, supporting a substantive update classification rather than a simple report publication announcement or regulatory filing.
2017-06-12 English
Interview with Pharmaxis Chief Executive Officer 1
Regulatory Filings Classification · 95% confidence The document is a media release dated 13 June 2017, containing an interview with the CEO discussing clinical trial results and a business update. It is a short text (795 characters) and does not contain any financial statements, regulatory filings, or detailed financial data. It is not an earnings release or investor presentation but rather a public announcement with a link to a video interview. This fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2017-06-12 English
Director Appointment 2 pages 121.6KB
Board/Management Information Classification · 100% confidence The document is a media release announcing the appointment of Dr Kathleen Metters to the Board of Directors of Pharmaxis. It focuses on biographical details and the strategic rationale for the appointment. There is no financial data, no discussion of financial results, no mention of shareholder votes, no regulatory filings, and no reference to any report publication. The content is clearly about a change in the company's board of directors. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 5532 characters, which is sufficient for a detailed announcement but does not contain financial statements or other report data.
2017-06-06 English
Initial Director's Interest Notice 2 pages 69.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, with no securities held or contracts noted. This type of document is a report of personal share transactions or interests by company directors. It is not a financial report, management announcement, or other corporate filing. Therefore, it fits the definition of Director's Dealing (DIRS). The document length is short and contains specific director interest disclosures, confirming the classification.
2017-06-06 English
Pharmaxis Set to Generate Further Euro 10m Milestone Payment 2 pages 127.3KB
Capital/Financing Update Classification · 95% confidence The document is a media release dated 15 May 2017 from Pharmaxis Ltd announcing milestone payments related to the clinical development of a drug discovery asset by Boehringer Ingelheim. It discusses milestone payments, clinical trial plans, and financial implications but does not contain detailed financial statements, regulatory filings, or comprehensive financial performance data. It is a corporate announcement about financing milestones and development updates rather than a full financial report or regulatory filing. Therefore, it fits best under Capital/Financing Update (CAP) as it provides updates on milestone payments and financing related to drug development.
2017-05-14 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.